Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: HB who wrote (242)	12/17/1997 6:15:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 717

Howard: Unfortunately the tendency seems to be for companies to reveal less and less about the details of their licensing agreements. (Or if they do give figures they're of the form of "up to umpteen million dollars if all milestones are met in all indications being explored" - yeah right). This is an exciting indication I've been wondering about, given that QLTIF seem to be doing well with it, and it's a very large market. See the following post: Message 1386462 Generally LuTex seems to work better than QLT's stuff, and doesn't have the nasty photosensitivity problems that QLT generally seems to have, at least with Photofrin. I think Miravant also has designs on the opthalmology area with a similar idea. Anyone follow them? Pity the rest of my stocks didn't look like PCYC today ... Peter